ArticleDiscover oncology2026
Metabolomic analysis for diagnosis of oral squamous cell carcinoma using machine learning.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC) undergoes significant metabolic reprogramming. Adopting metabolomics to identify altered metabolic enzymes and metabolites holds promise for the early and precise diagnosis of OSCC. However, most current workflows rely on single-perspective modeling and lack task-aware prioritization. They underextract metabolomic signals, limit classification robustness, and impede a traceable transition from untargeted discovery to targeted panels. Therefore, we propose Metabolomics-based Integrated Information Learning (MIIL), an interpretable framework for OSCC diagnosis and premalignant screening. MIIL prioritizes task-relevant metabolites to derive a compact biomarker panel for targeted assay development, while strengthening classification via decision-level fusion of heterogeneous learners. Initially, we collect 120 oral mucosa tissues from 40 OSCC patients, including 40 Cancer (CA) samples, 40 Margin-1 specimens (M1), and 40 Margin-2 tissues (M2). Moreover, MIIL conducts untargeted metabolomics analysis to identify the most significant differential metabolites contributing to OSCC diagnosis. Subsequently, targeted metabolomics techniques are exploited for in-depth analysis of amino acid metabolites. Finally, integrated learning models are combined via decision-level fusion of linear, probabilistic, and margin-based signals, supporting accurate OSCC classification. The final results demonstrate that this method excels in the CA.vs.M1, CA.vs.M2, and M1.vs.M2 diagnostic tasks, achieving mean accuracies of 88.33%, 91.67%, and 85.00%, respectively. Trial registration: Chinese Clinical Trial Registry (ChiCTR), ChiCTR2200064861; registered on 2023-04-23.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.